Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN).
Yoo AJ, Berkhemer OA, Fransen PSS, van den Berg LA, Beumer D, Lingsma HF, Schonewille WJ, Sprengers MES, van den Berg R, van Walderveen MAA, Beenen LFM, Wermer MJH, Nijeholt GJLÀ, Boiten J, Jenniskens SFM, Bot JCJ, Boers AMM, Marquering HA, Roos YBWEM, van Oostenbrugge RJ, Dippel DWJ, van der Lugt A, van Zwam WH, Majoie CBLM; MR CLEAN investigators.
Yoo AJ, et al. Among authors: nijeholt gjla.
Lancet Neurol. 2016 Jun;15(7):685-694. doi: 10.1016/S1474-4422(16)00124-1. Epub 2016 May 9.
Lancet Neurol. 2016.
PMID: 27302238
Clinical Trial.